調查記者凱瑟琳·埃班報導一個看似簡單的問題：學名藥真的與原廠藥一模一樣嗎？她為了尋找答案，歷經近十年的採訪、與舉發者會談、在全球四大洲的實地調查，和挖掘美國食品藥品監督管理局（FDA）的機密文件。在這驚醒人的演講中，她帶領我們深入了解海外製藥廠，揭露許多低成本學名藥背後的欺詐造假行為。

關於學名藥的一劑事實真相

Many generic drugs, relied on by 90 percent of patients in the US, are manufactured in overseas plants that routinely cut corners and falsify data. Investigations uncovered widespread fraud, dangerous impurities, and regulatory blind spots, including FDA inspections announced months in advance. Whistleblowers risked their careers to expose these practices, revealing a global system that sometimes puts patient lives in jeopardy for profit. True safety requires rigorous oversight, not trust alone.